Division of Urologic Oncology, The Ohio State University Comprehensive Cancer Center, 915 Olentangy River Road, 3rd Floor, Urology Suite 3100, Columbus, OH 43212, USA.
Division of Urologic Oncology, The Ohio State University Comprehensive Cancer Center, 915 Olentangy River Road, 3rd Floor, Urology Suite 3100, Columbus, OH 43212, USA.
Urol Clin North Am. 2023 May;50(2):311-323. doi: 10.1016/j.ucl.2023.01.013.
The role of surgery for patients with locally advanced and metastatic renal cell carcinoma (RCC) is not precisely defined in our contemporary era of systemic therapies. Research in this field is focused on the role of regional lymphadenectomy, along with indications and timing of cytoreductive nephrectomy and metastasectomy. As our understanding of the molecular and immunological basis of RCC continues to develop along with the advent of novel systemic therapies, prospective clinical trials will be critical in defining how surgery should be integrated into the treatment paradigm of advanced RCC.
对于局部晚期和转移性肾细胞癌 (RCC) 患者,手术的作用在我们的当代系统治疗时代尚未明确界定。该领域的研究集中在区域淋巴结清扫术的作用,以及减瘤性肾切除术和转移切除术的适应证和时机。随着我们对 RCC 的分子和免疫学基础的理解不断发展,以及新型系统治疗方法的出现,前瞻性临床试验对于确定如何将手术纳入晚期 RCC 的治疗模式至关重要。